Home Newsfeeds Gordon Haskett Downgrades Target to Hold

Gordon Haskett Downgrades Target to Hold

Gordon Haskett analyst Chuck Grom downgrades Target (NYSE:TGT) from Buy to Hold.

byBenzinga Newsdesk

December 21, 2022

1 minute read

Gordon Haskett analyst Chuck Grom downgrades Target (NYSE:TGT) from Buy to Hold.

Legal
News

“Carr Applauds Introduction Of Bipartisan Legislation To Ban TikTok; ‘The ANTI-SOCIAL CPP Act Would Protect Americans And Strengthen U.S. National Secuirty'” – FCC

By Benzinga Newsdesk

December 13, 3:03 PM

https://www.rubio.senate.gov/public/index.cfm/2022/12/rubio-gallagher-introduce-bipartisan-legislation-to-ban-tiktok

SPY

Betaville Saying Received Takeover Approach From Strategic Bidder For Fidelity National Information Services

By Benzinga Newsdesk

January 19, 11:09 AM

Fidelity National Information Services Inc, the US-listed payments company, is at the centre of takeover speculation.People following the situation have heard rumours Fidelity National Information Services Inc may have

FIS

Humanigen’s Lenzilumab Disappoints In NIH-Backed COVID-19 Study

By Vandana Singh

July 13, 7:39 AM

Humanigen Inc (NASDAQ: HGEN) has been informed of preliminary topline results from the ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.

HGEN

CSI Compressco And 2 Other Stocks Under $2 Insiders Are Buying

By Lisa Levin

September 21, 9:30 AM

The Dow Jones closed lower by around 75 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

ASPU

Gordon Haskett Downgrades Target to Hold

Related Posts

“Carr Applauds Introduction Of Bipartisan Legislation To Ban TikTok; ‘The ANTI-SOCIAL CPP Act Would Protect Americans And Strengthen U.S. National Secuirty'” – FCC

Betaville Saying Received Takeover Approach From Strategic Bidder For Fidelity National Information Services

Humanigen’s Lenzilumab Disappoints In NIH-Backed COVID-19 Study

CSI Compressco And 2 Other Stocks Under $2 Insiders Are Buying